Beyond Air Announces Proposed Public Offering and Concurrent Private Placement
Beyond Air, Inc. (XAIR)
Company Research
Source: GlobeNewswire
GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares to be issued and sold in the public offering. The public offering is subject to market and other conditions and there can be no assurance as to whether or when the public offering may be completed, or as to the actual size or terms of the public offering. Concurrently with the completion of the public offering, the Company expects to sell to certain investors in a private placement, a number of s
Show less
Read more
Impact Snapshot
Event Time:
XAIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XAIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XAIR alerts
High impacting Beyond Air, Inc. news events
Weekly update
A roundup of the hottest topics
XAIR
News
- Beyond Air, Inc. (NASDAQ: XAIR) had its price target lowered by analysts at Truist Financial Co. from $10.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]Yahoo! Finance
- Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and WarrantsGlobeNewswire
- Diabetic Foot Ulcers Market to Witness Upsurge Growth by 2032, Estimates DelveInsight | Leading Companies - Anterogen Co., Lavior Pharma, Vitruvian Medical Devices, Oneness Biotech Co., Energenesis Biomedical Co. [Yahoo! Finance]Yahoo! Finance
- Beyond Air, Inc. (NASDAQ:XAIR) Q3 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
XAIR
Earnings
- 2/12/24 - Beat
XAIR
Sec Filings
- 3/22/24 - Form 8-K
- 3/22/24 - Form 424B5
- 3/21/24 - Form 4
- XAIR's page on the SEC website